RSUME enhances glucocorticoid receptor SUMOylation and transcriptional activity

Molecular and Cellular Biology

Volumn 33, Issue 11, 2013, Pages 2116-2127

  Druker, Jimena ^a   Liberman, Ana C ^a   Antunica Noguerol, María ^a   Gerez, Juan ^a   Paez Pereda, Marcelo ^b   Rein, Theo ^b   Iñiguez Lluhí, Jorge A ^c   Holsboer, Florian ^b   Arzta, Eduardo ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID RECEPTOR; NUCLEAR RECEPTOR COACTIVATOR 2; SMALL INTERFERING RNA;

ARTICLE; CONTROLLED STUDY; FEMALE; GENE ACTIVITY; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PROCESSING; SUMOYLATION;

ANIMALS; ARGININE; CARRIER PROTEINS; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; HEAT-SHOCK RESPONSE; MUTATION; NERVE TISSUE PROTEINS; PROTEIN STRUCTURE, TERTIARY; RATS; RECEPTORS, GLUCOCORTICOID; SUMOYLATION; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84878975157     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01470-12     Document Type: Article

References (53)

1. Beato M, Chavez S, Truss M. 1996. Transcriptional regulation by steroid hormones. Steroids 61:240-251.
2. Barnes PJ. 1998. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Sci. (Lond.) 94:557-572.
3. Gross KL, Cidlowski JA. 2008. Tissue-specific glucocorticoid action: a family affair. Trends Endocrinol. Metab. 19:331-339.
4. Sapolsky RM, Romero LM, Munck AU. 2000. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocrinol. Rev. 21:55-89.
5. Ricketson D, Hostick U, Fang L, Yamamoto KR, Darimont BD. 2007. A conformational switch in the ligand-binding domain regulates the dependence of the glucocorticoid receptor on Hsp90. J. Mol. Biol. 368:729-741.
6. Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, Consler TG, Parks DJ, Stewart EL, Willson TM, Lambert MH, Moore JT, Pearce KH, Xu HE. 2002. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110:93-105.
7. Davies L, Karthikeyan N, Lynch JT, Sial EA, Gkourtsa A, Demonacos C, Krstic-Demonacos M. 2008. Cross talk of signaling pathways in the regulation of the glucocorticoid receptor function. Mol. Endocrinol. 22: 1331-1344.
8. Holmstrom S, Van Antwerp ME, Iniguez-Lluhi JA. 2003. Direct and distinguishable inhibitory roles forSUMOisoforms in the control of transcriptional synergy. Proc. Natl. Acad. Sci. U. S. A. 100:15758-15763.
9. Ismaili N, Garabedian MJ. 2004. Modulation of glucocorticoid receptor function via phosphorylation. Ann. N. Y. Acad. Sci. 1024:86-101.
10. Mason SA, Housley PR. 1993. Site-directed mutagenesis of the phosphorylation sites in the mouse glucocorticoid receptor. J. Biol. Chem. 268:21501-21504.
11. Tian S, Poukka H, Palvimo JJ, Janne OA. 2002. Small ubiquitin-related modifier-1 (SUMO-1) modification of the glucocorticoid receptor. Biochem. J. 367:907-911.
12. Wallace AD, Cidlowski JA. 2001. Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J. Biol. Chem. 276:42714-42721.
13. Hay RT. 2005. SUMO: a history of modification. Mol. Cell 18:1-12.
14. Melchior F. 2000. SUMO-nonclassical ubiquitin. Annu. Rev. Cell Dev. Biol. 16:591-626.
15. Gareau JR, Lima CD. 2010. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat. Rev. Mol. Cell Biol. 11:861-871.
16. Saitoh H, Hinchey J. 2000. Functional heterogeneity of small ubiquitinrelated protein modifiers SUMO-1 versus SUMO-2/3. J. Biol. Chem. 275:6252-6258.
17. Golebiowski F, Tatham MH, Nakamura A, Hay RT. 2010. Highstringency tandem affinity purification of proteins conjugated to ubiquitin- like moieties. Nat. Protoc. 5:873-882.
18. Tatham MH, Matic I, Mann M, Hay RT. 2011. Comparative proteomic analysis identifies a role for SUMO in protein quality control. Sci. Signal. 4:rs4. doi:10.1126/scisignal.2001484.
19. Doerks T, Copley RR, Schultz J, Ponting CP, Bork P. 2002. Systematic identification of novel protein domain families associated with nuclear functions. Genome Res. 12:47-56.
20. Carbia-Nagashima A, Gerez J, Perez-Castro C, Paez-Pereda M, Silberstein S, Stalla GK, Holsboer F, Arzt E. 2007. RSUME, a small RWDcontaining protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell 131:309-323.
21. Le Drean Y, Mincheneau N, Le Goff P, Michel D. 2002. Potentiation of glucocorticoid receptor transcriptional activity by sumoylation. Endocrinology 143:3482-3489.
22. Chupreta S, Brevig H, Bai L, Merchant JL, Iniguez-Lluhi JA. 2007. Sumoylation-dependent control of homotypic and heterotypic synergy by the Kruppel-type zinc finger protein ZBP-89. J. Biol. Chem. 282:36155-36166.
23. Subramanian L, Benson MD, Iniguez-Lluhi JA. 2003. A synergy control motif within the attenuator domain of CCAAT/enhancer-binding protein alpha inhibits transcriptional synergy through its PIASy-enhanced modification by SUMO-1 or SUMO-3. J. Biol. Chem. 278:9134-9141.
24. Abdel-Hafiz H, Takimoto GS, Tung L, Horwitz KB. 2002. The inhibitory function in human progesterone receptor N termini binds SUMO-1 protein to regulate autoinhibition and transrepression. J. Biol. Chem. 277: 33950-33956.
25. Iniguez-Lluhi JA, Pearce D. 2000. A common motif within the negative regulatory regions of multiple factors inhibits their transcriptional synergy. Mol. Cell. Biol. 20:6040-6050.
26. Poukka H, Karvonen U, Janne OA, Palvimo JJ. 2000. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc. Natl. Acad. Sci. U. S. A. 97:14145-14150.
27. Vu EH, Kraus RJ, Mertz JE. 2007. Phosphorylation-dependent sumoylation of estrogen-related receptor alpha1. Biochemistry 46:9795-9804.
28. Holmstrom SR, Chupreta S, So AY, Iniguez-Lluhi JA. 2008. SUMOmediated inhibition of glucocorticoid receptor synergistic activity depends on stable assembly at the promoter but not on DAXX. Mol. Endocrinol. 22:2061-2075.
29. Gottlicher M, Heck S, Doucas V, Wade E, Kullmann M, Cato AC, Evans RM, Herrlich P. 1996. Interaction of the Ubc9 human homologue with c-Jun and with the glucocorticoid receptor. Steroids 61:257-262.
30. Cho S, Kagan BL, Blackford JA, Jr, Szapary D, Simons SS, Jr. 2005. Glucocorticoid receptor ligand binding domain is sufficient for the modulation of glucocorticoid induction properties by homologous receptors, coactivator transcription intermediary factor 2, and Ubc9. Mol. Endocrinol. 19:290-311.
31. Kaul S, Blackford JA, Jr, Cho S, Simons SS, Jr. 2002. Ubc9 is a novel modulator of the induction properties of glucocorticoid receptors. J. Biol. Chem. 277:12541-12549.
32. Kotaja N, Aittomaki S, Silvennoinen O, Palvimo JJ, Janne OA. 2000. ARIP3 (androgen receptor-interacting protein 3) and other PIAS (protein inhibitor of activated STAT) proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation. Mol. Endocrinol. 14:1986-2000.
33. Tirard M, Jasbinsek J, Almeida OF, Michaelidis TM. 2004. The manifold actions of the protein inhibitor of activated STAT proteins on the transcriptional activity of mineralocorticoid and glucocorticoid receptors in neural cells. J. Mol. Endocrinol. 32:825-841.
34. Lee GS, Simons SS, Jr. 2011. Ligand binding domain mutations of the glucocorticoid receptor selectively modify the effects with, but not binding of, cofactors. Biochemistry 50:356-366.
35. Tao YG, Xu Y, Xu HE, Simons SS, Jr. 2008. Mutations of glucocorticoid receptor differentially affect AF2 domain activity in a steroid-selective manner to alter the potency and efficacy of gene induction and repression. Biochemistry 47:7648-7662.
36. Kotaja N, Karvonen U, Janne OA, Palvimo JJ. 2002. The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J. Biol. Chem. 277:30283-30288.
37. Teyssier C, Ou CY, Khetchoumian K, Losson R, Stallcup MR. 2006. Transcriptional intermediary factor 1alpha mediates physical interaction and functional synergy between the coactivator-associated arginine methyltransferase 1 and glucocorticoid receptor-interacting protein 1 nuclear receptor coactivators. Mol. Endocrinol. 20:1276-1286.
38. Desterro JM, Rodriguez MS, Hay RT. 1998. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol. Cell 2:233-239.
39. Jaffray EG, Hay RT. 2006. Detection of modification by ubiquitin-like proteins. Methods 38:35-38.
40. Tatham MH, Jaffray E, Vaughan OA, Desterro JM, Botting CH, Naismith JH, Hay RT. 2001. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J. Biol. Chem. 276:35368-35374.
41. Ayaydin F, Dasso M. 2004. Distinct in vivo dynamics of vertebrateSUMO paralogues. Mol. Biol. Cell 15:5208-5218.
42. Rupprecht R, Arriza JL, Spengler D, Reul JM, Evans RM, Holsboer F, Damm K. 1993. Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. Mol. Endocrinol. 7:597-603.
43. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498.
44. Paakinaho V, Makkonen H, Jaaskelainen T, Palvimo JJ. 2010. Glucocorticoid receptor activates poised FKBP51 locus through long-distance interactions. Mol. Endocrinol. 24:511-525.
45. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG, Palvimo JJ, Hay RT. 2008. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 10:538-546.
46. Rytinki M, Kaikkonen S, Sutinen P, Paakinaho V, Rahkama V, Palvimo JJ. 2012. Dynamic SUMOylation is linked to the activity cycles of androgen receptor in the cell nucleus. Mol. Cell. Biol. 32:4195-4205.
47. Kotaja N, Karvonen U, Janne OA, Palvimo JJ. 2002. PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol. Cell. Biol. 22:5222-5234.
48. Yokota K, Shibata H, Kurihara I, Kobayashi S, Suda N, Murai-Takeda A, Saito I, Kitagawa H, Kato S, Saruta T, Itoh H. 2007. Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9. J. Biol. Chem. 282:1998-2010.
49. Suda N, Shibata H, Kurihara I, Ikeda Y, Kobayashi S, Yokota K, Murai-Takeda A, Nakagawa K, Oya M, Murai M, Rainey WE, Saruta T, Itoh H. 2011. Coactivation of SF-1-mediated transcription of steroidogenic enzymes by Ubc9 and PIAS1. Endocrinology 152:2266-2277.
50. Li DP, Periyasamy S, Jones TJ, Sanchez ER. 2000. Heat and chemical shock potentiation of glucocorticoid receptor transactivation requires heat shock factor (HSF) activity. Modulation of HSF by vanadate and wortmannin. J. Biol. Chem. 275:26058-26065.
51. Sanchez ER, Hu JL, Zhong S, Shen P, Greene MJ, Housley PR. 1994. Potentiation of glucocorticoid receptor-mediated gene expression by heat and chemical shock. Mol. Endocrinol. 8:408-421.
52. Leonard MO, Godson C, Brady HR, Taylor CT. 2005. Potentiation of glucocorticoid activity in hypoxia through induction of the glucocorticoid receptor. J. Immunol. 174:2250-2257.
53. Sanchez ER. 1992. Heat shock induces translocation to the nucleus of the unliganded glucocorticoid receptor. J. Biol. Chem. 267:17-20.